Teva Pharmaceutical Industries Limited (VIE:TEVA)
Austria · Delayed Price · Currency is EUR | Market Cap | 29.88B +64.9% |
| Revenue (ttm) | 14.70B +4.3% |
| Net Income | 1.20B |
| EPS | 1.03 |
| Shares Out | n/a |
| PE Ratio | 24.88 |
| Forward PE | 10.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 165 |
| Open | 25.70 |
| Previous Close | 25.30 |
| Day's Range | 25.70 - 25.70 |
| 52-Week Range | 11.30 - 31.00 |
| Beta | n/a |
| RSI | 30.52 |
| Earnings Date | May 6, 2026 |
About VIE:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
The 3 Best Stocks to Invest $1,000 in Right Now
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising pr...
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding
Form 13Fs help investors track which stocks and exchange-traded funds (ETFs) Wall Street's most successful money managers bought and sold in the latest quarter. Profit-taking looks to have been on bil...
Baron Health Care Fund Q4 2025 Contributors And Detractors
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com...
The Best Healthcare Stock to Invest $1,000 in Right Now
Teva Pharmaceutical Industries has more than doubled in price over the past year. The Israeli drugmaker, formerly known for producing generics, has made a major move into the specialty drugs space.
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole
Teva Pharmaceutical Industries is a large manufacturer of generic drugs. The company is working to expand into more complex generics and to develop its own drugs.
Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetiz...
Teva to Present at the Upcoming Investor Conferences in March
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...
U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...
Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript
Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results Transcript
Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients
Teva and Sanofi SA (NASDAQ: SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.
Teva and Sanofi's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease
Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, ...
Teva Pharmaceutical profit, revenue rise in fourth quarter
Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in fourth-quarter profit, boosted by sales of its branded drugs as well as a milestone payment to begin a late stage st...
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Ja...
Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD'
PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partner...
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the N...
Teva Is No Longer A Turnaround Story, It's A Growth One
Teva Pharmaceutical (TEVA) remains a Buy, with specialty drugs, margin expansion, and the Royalty Pharma partnership driving further upside despite a 112% rally. TEVA's specialty pipeline—AUSTEDO, UZE...
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an...
Why Investors Are So Optimistic on Teva
Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard F...